Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Arch Dermatol Res ; 315(9): 2655-2660, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37606744

RESUMEN

It has been suggested that vitamin C is involved in suppressing stress oxidation signaling in vitiligo disease. However, the effect of vitamin C supplementation on stress oxidative factors has not been investigated in vitiligo subjects. This study was designed to examine the effects on vitamin C supplementation on serum levels of stress oxidative factors and regimentation in vitiligo patients. Forty-four vitiligo patients will be recruited in this study. After block matching for sex and number of phototherapy sessions, they will be randomly assigned to receive 1000 mg/d vitamin C or placebo for 8 weeks. The weight, height, and waist circumference of participants will be measured. Determination of serum stress oxidative indices (CAT, SOD, GPX, MDA, TOS, TAC) will be done at study baseline and at the end of the trial. Also, the regimentation will be determined using the VASI score. This is the first randomized controlled trial that will determine the effect of vitamin C supplementation on serum levels of stress oxidative indices and regimentation in vitiligo patients. The results of this trial will provide clinical evidence on the effectiveness of vitamin C supplementation in controlling oxidative stress in vitiligo patients. Trial registration number: This study is registered in the Iranian Registry of Clinical Trials website (available at http://www.irct.ir , identifier: IRCT20230123057193N1), Registration date: 2023/04/17.


Asunto(s)
Hipopigmentación , Vitíligo , Humanos , Vitíligo/tratamiento farmacológico , Ácido Ascórbico/uso terapéutico , Irán , Piel , Estrés Oxidativo
2.
Biomed Pharmacother ; 142: 112024, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34399200

RESUMEN

Silymarin contains a group of closely-related flavonolignan compounds including silibinin, and is extracted from Silybum marianum species, also called milk thistle. Silymarin has been shown to protect the liver in both experimental models and clinical studies. The chemopreventive activity of silymarin has shown some efficacy against cancer both in vitro and in vivo. Silymarin can modulate apoptosis in vitro and survival in vivo, by interfering with the expression of cell cycle regulators and apoptosis-associated proteins. In addition to its anti-metastatic activity, silymarin has also been reported to exhibit anti-inflammatory activity. The chemoprotective effects of silymarin and silibinin (its major constituent) suggest they could be applied to reduce the side effects and increase the anti-cancer effects of chemotherapy and radiotherapy in various cancer types, especially in gastrointestinal cancers. This review examines the recent studies and summarizes the mechanistic pathways and down-stream targets of silymarin in the therapy of gastrointestinal cancer.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Neoplasias Gastrointestinales/tratamiento farmacológico , Silimarina/farmacología , Animales , Antiinflamatorios/farmacología , Apoptosis/efectos de los fármacos , Humanos , Silybum marianum/química , Extractos Vegetales/química
3.
Phytother Res ; 35(9): 4834-4897, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34173992

RESUMEN

Gastrointestinal (GI) cancers with a high global prevalence are a leading cause of morbidity and mortality. Accordingly, there is a great need to develop efficient therapeutic approaches. Curcumin, a naturally occurring agent, is a promising compound with documented safety and anticancer activities. Recent studies have demonstrated the activity of curcumin in the prevention and treatment of different cancers. According to systematic studies on curcumin use in various diseases, it can be particularly effective in GI cancers because of its high bioavailability in the gastrointestinal tract. Nevertheless, the clinical applications of curcumin are largely limited because of its low solubility and low chemical stability in water. These limitations may be addressed by the use of relevant analogues or novel delivery systems. Herein, we summarize the pharmacological effects of curcumin against GI cancers. Moreover, we highlight the application of curcumin's analogues and novel delivery systems in the treatment of GI cancers.


Asunto(s)
Curcumina , Neoplasias Gastrointestinales , Disponibilidad Biológica , Curcumina/uso terapéutico , Neoplasias Gastrointestinales/tratamiento farmacológico , Humanos
4.
Curr Drug Targets ; 21(5): 509-518, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31721700

RESUMEN

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive death of dopaminergic neurons in the substantia nigra pars compacta (SNc). PD is a multifactorial disorder, with several different factors being suggested to play a synergistic pathophysiological role, including oxidative stress, autophagy, underlying pro-inflammatory events and neurotransmitters abnormalities. Overall, PD can be viewed as the product of a complex interaction of environmental factors acting on a given genetic background. The importance of this subject has gained more attention to discover novel therapies to prevent as well as treat PD. According to previous research, drugs used to treat PD have indicated significant limitations. Therefore, the role of flavonoids has been extensively studied in PD treatment. Quercetin, a plant flavonol from the flavonoid group, has been considered as a supplemental therapy for PD. Quercetin has pharmacological functions in PD by controlling different molecular pathways. Although few studies intended to evaluate the basis for the use of quercetin in the context of PD have been conducted so far, at present, there is very little evidence available addressing the underlying mechanisms of action. Various principal aspects of these treatment procedures remain unknown. Here, currently existing knowledge supporting the use of quercetin for the clinical management of PD has been reviewed.


Asunto(s)
Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Quercetina/farmacología , Quercetina/uso terapéutico , Animales , Antioxidantes/metabolismo , Suplementos Dietéticos , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas Dopaminérgicas/metabolismo , Humanos , Enfermedad de Parkinson/etiología , Quercetina/metabolismo , Transmisión Sináptica/efectos de los fármacos
5.
Chemistry ; 13(2): 598-603, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17013962

RESUMEN

The characterisation of a series of compounds obtained from Woollins' reagent (W.R.) offers a novel approach to organometallic coordination polymers. The syntheses were achieved by nucleophilic ring-opening reactions of W.R. with metal salts and crystallisation using solvent-diffusion techniques. One-dimensional coordination polymers are formed as a result, and we demonstrate that the dimensionality of the polymers can be influenced by using hydrated metal salts or by the construction of heterometallic arrangements.


Asunto(s)
Aniones/química , Compuestos Organometálicos/química , Polímeros/química , Aniones/síntesis química , Cristalografía por Rayos X , Espectroscopía de Resonancia Magnética , Metales Alcalinos/química , Modelos Moleculares , Conformación Molecular , Compuestos Organometálicos/síntesis química , Compuestos Organofosforados/síntesis química , Compuestos Organofosforados/química , Polímeros/síntesis química , Selenio/química , Compuestos de Selenio/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA